Our Statement Following the FDA’s Advisory Committee Vote on NurOwn

We are grateful to everyone who shared their perspectives on NurOwn with the FDA and we thank all the people living with ALS who participated in the NurOwn trials and expanded access program. We call on BrainStorm to immediately unblind the participants in its Phase 3 trial, which concluded over three years ago, so that participants and their family members can know if they were on NurOwn or placebo.

Today’s events underscore the need to develop and test as many new therapies as possible so we can find new treatments and cures for people living with ALS. We have a lot of work to do to ensure ALS is livable for everyone, everywhere, but there are many signs of hope.

We are currently funding at least 30 new potential therapies in the pipeline. We have seen funding from federal and state governments for ALS research and care at unprecedented levels. And more people living with ALS around the U.S. have greater access to high quality care than ever before.

We will continue working urgently to do everything we can to support people living with ALS and their loved ones.